Performance of Coronary Risk Scores Among Patients With Chest Pain in the Emergency Department

Background

Both the modified History, Electrocardiogram, Age, Risk factors and Troponin (HEART) score and the Emergency Department Assessment of Chest pain Score (EDACS) can identify patients with possible acute coronary syndrome (ACS) at low risk (<1%) for major adverse cardiac events (MACE).

Relationship of Aging and Incident Comorbidities to Stroke Risk in Patients With Atrial Fibrillation

Background

When assessing ischemic stroke risk in patients with atrial fibrillation (AF), the CHA₂DS₂-VASc score is calculated based on the baseline risk factors, and the outcomes are determined after a follow-up period. However, the stroke risk in patients with AF does not remain static, and with time, patients get older and accumulate more comorbidities.

Digoxin and Mortality in Patients With Atrial Fibrillation

Background

Digoxin is widely used in patients with atrial fibrillation (AF).

Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk of Heart Failure

Background

Long-term continuous monitoring detects short-lasting, subclinical atrial fibrillation (SCAF) in approximately one-third of older individuals with cardiovascular conditions. The relationship between SCAF, its progression, and the development of heart failure (HF) is unclear.

Gene Expression of Atrial Calcium-Handling Proteins in Patients with Rheumatic Heart Disease and Atrial Fibrillation

Objectives To investigate the gene expression of calcium - handling proteins in patients with rheumatic heart disease (RHD) and atrial fibrillation (AF) . Methods A total of 50 patients with rheumatic mitral valve disease were included. According to cardiac rhythm and duration of episode of AF, patients were divided into four groups: sinus rhythm group, paroxysmal AF group, persistent AF for less than 6 months group and persistent AF for more than 6 months group. Atrial tissue was obtained from the right atrial appendage, the right atrial free wall and the left atrial appendage respectively during open heart surgery. Total RNA was isolated and reversly transcribed into cDNA. In a semi - quantitative polymerase chain reaction the cDNA of interest and of glyceralde-hyde3 - phosphate dehydrogenase (GAPDH) were amplified and separated by ethidium bromide - stained gel electrophoresis. Multiple liner regress was used for correlation between the mRNA amount and age, sex, right atrial diameter (RAd) and left a     

Sex Differences in Atrial Fibrillation—Update on Risk Assessment,Treatment, and Long-Term Risk

Purpose of review

Atrial fibrillation (AF) is a growing health problem worldwide. While the disease plagues both men and women, this arrhythmia does not affect both sexes equally. Women are more likely to have major adverse outcomes such as stroke and its sequela; however, recent data on stroke prevention show improving outcomes. The purpose of this review of the recent literature is to summarize important updates on risk scores and management of patients with AF.

Recent findings

It has been well known that women have a higher risk of strokes than men when untreated or when treated with warfarin. Current risk scores emphasizing new risk factors such as the higher risk of strokes in women have been incorporated into clinical guidelines. However, with the use of direct oral anticoagulants, this sex disparity on stroke is no longer seen and women have less major bleeding than men. The use of cardiac glycosides is associated with increased incidence of breast cancer, and this medication is used more in women. Procedural complications for the management of AF are higher in women.

Summary

The study of the pathophysiology of AF and its management is a rapidly evolving area of cardiovascular medicine. Sex-specific data is necessary to achieve advances in the field and improve the outcomes in both men and women.

     

Performance of Prognostic Risk Scores in Heart Failure Patients: Do Sex Differences Exist?

BackgroundSex differences in the performance of prognostic risk scores in heart failure (HF) patients have not previously been investigated. We examined the performance of 2 commonly used scores in predicting mortality and a composite end point consisting of ventricular assist device, heart transplantation, or mortality in women vs men with HF.MethodsThis was a retrospective study of 1,136 (25% women) consecutive ambulatory adult HF patients with reduced left ventricular ejection fraction (≤ 40%) followed at a single institution from 2000 to 2012. Discrimination, calibration, and absolute risk reclassification of the Seattle Heart Failure Model (SHFM) and the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) score to predict 1- and 3-year outcomes were compared between women and men.ResultsAt 1- and 3-year follow-ups, 116 (22% women) and 231 (21% women) patients died, respectively. Survival was equal between sexes (P = 0.41). The SHFM and the MAGGIC score showed similar discriminatory capacity in women (c-statistics 0.84, 95% CI 0.77-0.92, and 0.74, 95% CI 0.64-0.83) and men (c-statistics 0.74, 95% CI 0.69-0.79, and 0.70, 95% CI 0.64-0.75). There was no difference in the predicted and observed 1-year mortality by the scores in both sexes. Compared with the SHFM, the MAGGIC score better reclassified 10% (95% CI 7%-14%) of women and 18% (95% CI 15%-20%) of men. At 3-year follow-up, similar results were seen for discrimination, whereas both scores overestimated mortality with more marked overestimation in women. The results were reproducible for the composite end point, with improved calibration at 3-year follow-up in both scores.ConclusionsOur findings support the use of the MAGGIC score in both women and men owing to better risk classification.     

Elevated Incidence of Atrial Fibrillation and Stroke in Patients With Atrial Flutter—A Population-Based Study

Background

The risk of stroke from atrial flutter and its relationship with progression to atrial fibrillation (AF) is unclear. This study describes the incidence of AF and stroke in patients with atrial flutter, and whether atrial flutter ablation attenuates the incidence of AF and stroke.

Does CHA2DS2-VASc Improve Stroke Risk Stratification in Postmenopausal Women with Atrial Fibrillation?

Background

Risk stratification of atrial fibrillation patients with a congestive heart failure (C), hypertension (H), age ≥ 75 (A), diabetes (D), stroke or transient ischemic attack (TIA) (S₂) (CHADS₂) score of <2 remains imprecise, particularly in women. Our objectives were to validate the CHADS₂ and congestive heart failure (C), hypertension (H), age ≥ 75 (A₂), diabetes (D), stroke, TIA or prior thromboembolic disease (S₂)- vascular disease (V), age 65-74 (A), female gender (S) (CHA₂DS₂-VASc) stroke risk scores in a healthy cohort of American women with atrial fibrillation and to determine whether CHA₂DS₂-VASc further risk-stratifies individuals with a CHADS₂ score of <2.

Methods

We identified a cohort of 5981 women with atrial fibrillation not on warfarin at baseline (mean age 65.9 ± 7.2 years) enrolled in the Women's Health Initiative and followed for a median of 11.8 years. Univariate and multivariate proportional hazards analyses were used to examine these 2 risk scores, with main outcome measures being annualized event rates of ischemic stroke or transient ischemic attack stratified by risk score.

Results

Annualized stroke/transient ischemic attack rates ranged from 0.36% to 2.43% with increasing CHADS₂ score (0-4+) (hazard ratio [HR] 1.57; 95% confidence interval [CI], 1.45-1.71 for each 1-point increase) and 0.20%-2.02% with increasing CHA₂DS₂-VASc score (1-6+) (HR 1.50; 95% CI, 1.41-1.60 for each 1-point increase). CHA₂DS₂-VASc had a higher c statistic than CHADS₂: 0.67 (95% CI, 0.65-0.69) versus 0.65 (95% CI, 0.62-0.67), P <.01. For CHADS₂ scores <2, stroke risk almost doubled with every additional CHA₂DS₂-VASc point.

Conclusions

Although both CHADS₂, and CHA₂DS₂-VASc are predictive of stroke risk in postmenopausal women with atrial fibrillation, CHA₂DS₂-VASc further risk-stratifies patients with a CHADS₂ score <2.     

The Relation of Atrial Fibrillation and Inflammation Do Inflammation Imply the Pathogenesis of Atrial Fibrillation？

Atrial fibrillation （AF）, the most commonly encountered arrhythmia in clinical practice, is associated with a 2-fold increase in total cardiovascular mortality, as well as the potential for substantial morbidity, including stroke, congestive heart failure, and cardiomyopathy. Its incidence and prevalence are increasing, and it represents a growing clinical and economic burden. Owing to relative inefficacy and side effects of current pharmacological and non-pharmacological therapy for AF, it remains a great challenge to improve primary and secondary AF prevention strategies to reduce this potentially enormous health burden.     

Is Pursuit of Termination of Atrial Fibrillation During Catheter Ablation of Great Value in Patients with Longstanding Persistent Atrial Fibrillation?

Termination of Atrial Fibrillation During Catheter Ablation Predicts Better Outcome . Background: The reliable endpoint for ablation of longstanding persistent atrial fibrillation (LPAF) has not been clearly established. Methods and Results: This study included 140 patients who underwent catheter ablation for drug‐refractory LPAF. A stepwise ablation approach included circumferential pulmonary vein isolation followed by left atrial and right atrial complex fractionated electrogram‐guided ablation. Atrial fibrillation (AF) was terminated by radiofrequency application during catheter ablation in 95 patients (67.9%). Among them, 33 patients (23.6%) converted to sinus rhythm directly, whereas 62 patients (44.3%) via atrial tachycardias (ATs). Patients in whom AF terminated during the index procedure had a lower recurrence rate of atrial arrhythmia than patients in whom AF did not terminate (45.3% vs 68.9%, P = 0.009, follow‐up 18.7 ± 7.6 months). Among patients in whom AF terminated, there was no significant difference in recurrence rate according to the termination mode, whether converted to AT or not (P = NS). However, patients who converted to AT had a higher recurrence rate of AT (54.8% vs 81%; P = 0.016). Multivariable logistic regression analysis demonstrated that termination of AF during ablation (HR 0.440; 95% CI: 0.200–0.969, P = 0.041) and structural heart disease (HR 2.633; 95% CI: 1.211–5.723; P = 0.015) were significant independent factors predicting the recurrence of atrial arrhythmia. Conclusions: Termination of AF during catheter ablation is associated with a better clinical outcome in patients with LPAF. (J Cardiovasc Electrophysiol, Vol. 23 pp. 1051‐1058, October 2012)